image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 9.96
-5.41 %
$ 1.6 B
Market Cap
-49.8
P/E
1. INTRINSIC VALUE

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform.[ Read More ]

The intrinsic value of one CERT stock under the base case scenario is HIDDEN Compared to the current market price of 9.96 USD, Certara, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CERT

image
FINANCIALS
354 M REVENUE
5.57%
-40.8 M OPERATING INCOME
-125.38%
-55.4 M NET INCOME
-375.79%
82.8 M OPERATING CASH FLOW
-10.58%
-79.6 M INVESTING CASH FLOW
-185.77%
-9.45 M FINANCING CASH FLOW
-28.30%
94.8 M REVENUE
1.61%
2.59 M OPERATING INCOME
185.84%
-1.37 M NET INCOME
89.10%
17 M OPERATING CASH FLOW
73.09%
-5.51 M INVESTING CASH FLOW
9.99%
-5.6 M FINANCING CASH FLOW
-49.27%
Balance Sheet Decomposition Certara, Inc.
image
Current Assets 340 M
Cash & Short-Term Investments 235 M
Receivables 93.3 M
Other Current Assets 12 M
Non-Current Assets 1.22 B
Long-Term Investments 1.15 M
PP&E 12.3 M
Other Non-Current Assets 1.21 B
Current Liabilities 130 M
Accounts Payable 5.17 M
Short-Term Debt 7.4 M
Other Current Liabilities 117 M
Non-Current Liabilities 386 M
Long-Term Debt 295 M
Other Non-Current Liabilities 91.1 M
EFFICIENCY
Earnings Waterfall Certara, Inc.
image
Revenue 354 M
Cost Of Revenue 141 M
Gross Profit 213 M
Operating Expenses 254 M
Operating Income -40.8 M
Other Expenses 14.6 M
Net Income -55.4 M
RATIOS
60.20% GROSS MARGIN
60.20%
-11.51% OPERATING MARGIN
-11.51%
-15.62% NET MARGIN
-15.62%
-5.29% ROE
-5.29%
-3.54% ROA
-3.54%
-3.06% ROIC
-3.06%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Certara, Inc.
image
Net Income -55.4 M
Depreciation & Amortization 56.1 M
Capital Expenditures -15.3 M
Stock-Based Compensation 28.3 M
Change in Working Capital -4.72 M
Others 75.7 M
Free Cash Flow 67.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Certara, Inc.
image
Wall Street analysts predict an average 1-year price target for CERT of $17 , with forecasts ranging from a low of $13 to a high of $23 .
CERT Lowest Price Target Wall Street Target
13 USD 30.52%
CERT Average Price Target Wall Street Target
17 USD 70.68%
CERT Highest Price Target Wall Street Target
23 USD 130.92%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Certara, Inc.
image
Sold
0-3 MONTHS
638 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
442 K USD 2
9-12 MONTHS
216 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 07, 2024
Sell 59.7 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 5409
11.03 USD
2 months ago
Sep 09, 2024
Sell 578 K USD
Pedersen Leif E
PRESIDENT, CHIEF COMMERCAL OFF
- 51224
11.29 USD
7 months ago
Apr 02, 2024
Sell 88.2 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 5264
16.76 USD
7 months ago
Apr 02, 2024
Sell 11.5 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 649
17.72 USD
7 months ago
Apr 02, 2024
Sell 50.7 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 3024
16.75 USD
7 months ago
Apr 02, 2024
Sell 5.8 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 328
17.67 USD
7 months ago
Apr 02, 2024
Sell 79.5 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 4740
16.77 USD
7 months ago
Apr 02, 2024
Sell 7.5 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 422
17.77 USD
7 months ago
Apr 01, 2024
Sell 54 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
18 USD
8 months ago
Mar 04, 2024
Sell 54.8 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
18.28 USD
8 months ago
Feb 20, 2024
Sell 90 K USD
SMITH PATRICK F
PRESIDENT, DRUG DEV SOLUTIONS
- 5000
18 USD
9 months ago
Feb 12, 2024
Sell 108 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 6000
18 USD
10 months ago
Dec 26, 2023
Sell 108 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 6000
18 USD
1 year ago
Sep 11, 2023
Sell 748 K USD
Pedersen Leif E
PRESIDENT, CHIEF COMMERCAL OFF
- 51224
14.6 USD
1 year ago
Aug 22, 2023
Bought 76 K USD
BROSHY ERAN
Director
+ 4807
15.8 USD
1 year ago
Aug 21, 2023
Bought 3.11 K USD
BROSHY ERAN
Director
+ 193
16.1 USD
1 year ago
Jun 05, 2023
Sell 412 K USD
SMITH PATRICK F
PRESIDENT, INTEGRATED DRUG DEV
- 19104
21.55 USD
1 year ago
May 11, 2023
Sell 104 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
20.82 USD
1 year ago
Apr 14, 2023
Sell 118 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
23.66 USD
1 year ago
Mar 06, 2023
Sell 214 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 10000
21.45 USD
1 year ago
Feb 02, 2023
Sell 300 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 15000
20 USD
1 year ago
Dec 08, 2022
Sell 449 M USD
EQT Avatar Parent L.P.
Director
- 29954521
15 USD
1 year ago
Nov 22, 2022
Sell 797 K USD
Pedersen Leif E
director: PRESIDENT, SOFTWARE
- 51223
15.55 USD
2 years ago
Nov 14, 2022
Sell 64.2 K USD
SLAINE MASON P
Director
- 4207
15.27 USD
2 years ago
Nov 15, 2022
Sell 3.83 M USD
SLAINE MASON P
Director
- 245793
15.57 USD
2 years ago
Nov 14, 2022
Sell 178 K USD
WALSH MATTHEW M
Director
- 12059
14.74 USD
2 years ago
Nov 09, 2022
Sell 32.2 K USD
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
- 2387
13.48 USD
2 years ago
Aug 19, 2022
Bought 326 K USD
McLean Stephen M.
director:
+ 20000
16.32 USD
2 years ago
Aug 17, 2022
Bought 416 K USD
Schemick Michael Andrew
director: CHIEF FINANCIAL OFFICER
+ 25000
16.64 USD
2 years ago
Aug 16, 2022
Sell 177 K USD
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
- 10000
17.71 USD
2 years ago
Aug 16, 2022
Sell 104 M USD
EQT Fund Management S.a r.l.
director:
- 6004418
17.38 USD
2 years ago
Aug 16, 2022
Sell 3.17 M USD
SLAINE MASON P
director:
- 182475
17.38 USD
2 years ago
Jun 08, 2022
Sell 192 K USD
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
- 10000
19.16 USD
2 years ago
Jun 02, 2022
Sell 1.96 M USD
SLAINE MASON P
director:
- 100000
19.59 USD
2 years ago
May 31, 2022
Sell 28.5 M USD
EQT Fund Management S.a r.l.
director:
- 1500000
19 USD
2 years ago
Apr 01, 2022
Sell 74.7 K USD
SMITH PATRICK F
director: PRESIDENT, INTEGRATED DRUG DEV
- 3352
22.29 USD
2 years ago
Mar 16, 2022
Sell 60 K USD
Traynor Richard M.
director: SVP AND GENERAL COUNSEL
- 3000
20 USD
2 years ago
Mar 16, 2022
Sell 2.53 M USD
SLAINE MASON P
director:
- 125000
20.25 USD
2 years ago
Mar 16, 2022
Sell 1.26 M USD
Feehery William F
director: CHIEF EXECUTIVE OFFICER
- 62485
20.17 USD
2 years ago
Mar 11, 2022
Sell 558 K USD
Feehery William F
director: CHIEF EXECUTIVE OFFICER
- 27515
20.29 USD
2 years ago
Feb 18, 2022
Sell 1.64 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 70294
23.31 USD
2 years ago
Feb 18, 2022
Sell 113 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 4706
23.93 USD
2 years ago
Feb 17, 2022
Sell 1.27 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 53407
23.83 USD
2 years ago
Feb 17, 2022
Sell 750 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 30075
24.93 USD
2 years ago
Feb 17, 2022
Sell 166 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 6518
25.49 USD
2 years ago
Feb 01, 2022
Sell 934 K USD
SLAINE MASON P
Director
- 35199
26.53 USD
2 years ago
Feb 01, 2022
Sell 397 K USD
SLAINE MASON P
Director
- 14801
26.8 USD
2 years ago
Jan 26, 2022
Sell 78 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
26.01 USD
2 years ago
Jan 26, 2022
Sell 588 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 23804
24.72 USD
2 years ago
Jan 26, 2022
Sell 1.31 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 51196
25.67 USD
2 years ago
Jan 20, 2022
Sell 138 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 5000
27.5 USD
2 years ago
Jan 18, 2022
Sell 137 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
27.44 USD
2 years ago
Jan 03, 2022
Sell 1.15 M USD
SLAINE MASON P
Director
- 40323
28.57 USD
2 years ago
Jan 03, 2022
Sell 279 K USD
SLAINE MASON P
Director
- 9677
28.88 USD
2 years ago
Dec 27, 2021
Sell 87.9 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
29.3 USD
2 years ago
Dec 23, 2021
Sell 733 K USD
CASHMAN JAMES E III
Director
- 25111
29.2 USD
2 years ago
Dec 22, 2021
Sell 577 K USD
CASHMAN JAMES E III
Director
- 19889
29 USD
2 years ago
Dec 22, 2021
Sell 2.14 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 75000
28.58 USD
2 years ago
Dec 20, 2021
Sell 210 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 7500
28 USD
2 years ago
Dec 17, 2021
Sell 131 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 5000
26.13 USD
2 years ago
Dec 13, 2021
Sell 1.4 M USD
SLAINE MASON P
Director
- 49900
28.05 USD
2 years ago
Dec 13, 2021
Sell 2.86 K USD
SLAINE MASON P
Director
- 100
28.55 USD
2 years ago
Dec 07, 2021
Sell 418 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 15151
27.58 USD
2 years ago
Dec 07, 2021
Sell 1.53 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 54849
27.82 USD
2 years ago
Dec 03, 2021
Sell 1.73 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 66500
25.99 USD
2 years ago
Dec 03, 2021
Sell 92.9 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 3500
26.54 USD
2 years ago
Nov 24, 2021
Sell 3.62 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 127521
28.4 USD
2 years ago
Nov 24, 2021
Sell 501 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 17479
28.66 USD
2 years ago
Nov 22, 2021
Sell 11.2 M USD
SLAINE MASON P
Director
- 376149
29.741 USD
2 years ago
Nov 22, 2021
Sell 241 M USD
EQT Avatar Parent L.P.
10 percent owner
- 8117655
29.741 USD
2 years ago
Nov 19, 2021
Sell 2.12 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 70000
30.31 USD
2 years ago
Nov 19, 2021
Sell 606 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 20000
30.3 USD
3 years ago
Nov 15, 2021
Sell 2.49 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 65896
37.83 USD
3 years ago
Nov 15, 2021
Sell 29.7 K USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 770
38.57 USD
3 years ago
Nov 15, 2021
Sell 1.87 M USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 49300
37.84 USD
3 years ago
Nov 15, 2021
Sell 27 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 700
38.56 USD
3 years ago
Nov 15, 2021
Sell 117 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
38.96 USD
3 years ago
Nov 15, 2021
Sell 556 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 14700
37.85 USD
3 years ago
Nov 15, 2021
Sell 11.6 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 300
38.66 USD
3 years ago
Nov 15, 2021
Sell 195 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
38.96 USD
3 years ago
Nov 11, 2021
Sell 669 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 16962
39.43 USD
3 years ago
Nov 11, 2021
Sell 184 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 4592
40.06 USD
3 years ago
Oct 27, 2021
Sell 2.94 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 74800
39.24 USD
3 years ago
Oct 27, 2021
Sell 7.95 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 200
39.76 USD
3 years ago
Oct 26, 2021
Sell 120 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
39.95 USD
3 years ago
Oct 26, 2021
Sell 120 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 3000
39.95 USD
3 years ago
Oct 21, 2021
Sell 236 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 6116
38.6 USD
3 years ago
Oct 20, 2021
Sell 489 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 12674
38.58 USD
3 years ago
Oct 19, 2021
Sell 53.1 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 1434
37.05 USD
3 years ago
Oct 19, 2021
Sell 690 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 18083
38.15 USD
3 years ago
Oct 19, 2021
Sell 18.6 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 483
38.56 USD
3 years ago
Oct 19, 2021
Sell 46.6 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 1210
38.55 USD
3 years ago
Oct 18, 2021
Sell 2.26 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 62049
36.42 USD
3 years ago
Oct 18, 2021
Sell 172 K USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 4618
37.33 USD
3 years ago
Oct 15, 2021
Sell 187 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
37.38 USD
3 years ago
Oct 15, 2021
Sell 187 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 5000
37.38 USD
3 years ago
Oct 01, 2021
Sell 554 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 16587
33.39 USD
3 years ago
Oct 01, 2021
Sell 94.7 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 2767
34.24 USD
3 years ago
Sep 27, 2021
Sell 108 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 3000
36 USD
3 years ago
Sep 27, 2021
Sell 108 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
36 USD
3 years ago
Sep 22, 2021
Sell 2.11 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 58146
36.24 USD
3 years ago
Sep 22, 2021
Sell 621 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 16854
36.83 USD
3 years ago
Sep 20, 2021
Sell 1.66 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 48097
34.46 USD
3 years ago
Sep 20, 2021
Sell 651 K USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 18570
35.03 USD
3 years ago
Sep 17, 2021
Sell 221 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 6265
35.32 USD
3 years ago
Sep 17, 2021
Sell 494 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 13735
35.96 USD
3 years ago
Sep 13, 2021
Sell 399 M USD
EQT Avatar Parent L.P.
10 percent owner
- 13394635
29.799 USD
3 years ago
Sep 13, 2021
Sell 18.5 M USD
SLAINE MASON P
Director
- 620668
29.799 USD
3 years ago
Sep 09, 2021
Sell 202 K USD
Pedersen Leif E
PRESIDENT, SOFTWARE
- 6241
32.4 USD
3 years ago
Sep 09, 2021
Sell 165 K USD
Pedersen Leif E
PRESIDENT, SOFTWARE
- 4950
33.38 USD
3 years ago
Sep 09, 2021
Sell 533 K USD
Pedersen Leif E
PRESIDENT, SOFTWARE
- 15447
34.5 USD
3 years ago
Sep 09, 2021
Sell 849 K USD
Pedersen Leif E
PRESIDENT, SOFTWARE
- 24085
35.25 USD
3 years ago
Sep 09, 2021
Sell 18 K USD
Pedersen Leif E
PRESIDENT, SOFTWARE
- 500
36.1 USD
3 years ago
Sep 02, 2021
Sell 131 K USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 3900
33.51 USD
3 years ago
Sep 02, 2021
Sell 64.9 K USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 1900
34.15 USD
3 years ago
Sep 02, 2021
Sell 1.78 M USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 48462
36.64 USD
3 years ago
Sep 02, 2021
Sell 7.44 K USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 200
37.21 USD
3 years ago
Sep 01, 2021
Sell 626 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 18554
33.76 USD
3 years ago
Sep 01, 2021
Sell 27.4 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 800
34.24 USD
3 years ago
Sep 01, 2021
Sell 653 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 19409
33.66 USD
3 years ago
Sep 01, 2021
Sell 361 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 10591
34.06 USD
3 years ago
Aug 30, 2021
Sell 302 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 9000
33.5 USD
3 years ago
Aug 25, 2021
Sell 755 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 24308
31.08 USD
3 years ago
Aug 25, 2021
Sell 1.59 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 50692
31.37 USD
3 years ago
Aug 24, 2021
Sell 225 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 7500
30 USD
3 years ago
Aug 19, 2021
Sell 354 K USD
Choe Jieun W.
CHIEF STRATEGY & MARKETING
- 12500
28.34 USD
3 years ago
Aug 16, 2021
Sell 229 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 8000
28.58 USD
3 years ago
Aug 16, 2021
Sell 1.84 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 65267
28.21 USD
3 years ago
Aug 16, 2021
Sell 40.5 K USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 1400
28.9 USD
3 years ago
Aug 16, 2021
Sell 143 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 5000
28.58 USD
3 years ago
Aug 11, 2021
Sell 533 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 19354
27.54 USD
3 years ago
Aug 02, 2021
Sell 189 M USD
EQT Avatar Parent L.P.
10 percent owner
- 7252632
26 USD
3 years ago
Jul 28, 2021
Sell 1.96 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 75000
26.16 USD
3 years ago
Jul 26, 2021
Sell 78.8 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
26.27 USD
3 years ago
Jul 19, 2021
Sell 1.62 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 66667
24.37 USD
3 years ago
Jul 01, 2021
Sell 542 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 19354
28.03 USD
3 years ago
Jun 28, 2021
Sell 85.1 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 3000
28.38 USD
3 years ago
Jun 24, 2021
Sell 132 K USD
Traynor Richard M.
SVP AND GENERAL COUNSEL
- 5000
26.37 USD
3 years ago
Jun 23, 2021
Sell 1.98 M USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 74800
26.53 USD
3 years ago
Jun 23, 2021
Sell 5.43 K USD
Feehery William F
CHIEF EXECUTIVE OFFICER
- 200
27.17 USD
3 years ago
Jun 22, 2021
Sell 1.8 M USD
Schemick Michael Andrew
CHIEF FINANCIAL OFFICER
- 66666
26.94 USD
3 years ago
Jun 16, 2021
Sell 135 K USD
Edge Justin
PRES., REGULATORY & ACCESS
- 5000
27.015 USD
3 years ago
Jun 14, 2021
Sell 449 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 16347
27.49 USD
3 years ago
Jun 14, 2021
Sell 84.5 K USD
Aspbury Robert
PRESIDENT, SIMCYP
- 3007
28.11 USD
3 years ago
Jun 11, 2021
Sell 1.6 M USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 62445
25.7 USD
3 years ago
Jun 11, 2021
Sell 1.18 M USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 46079
25.71 USD
3 years ago
Jun 11, 2021
Sell 10.6 K USD
Rayner Craig R.
PRESIDENT, INTEGRATED DRUG DEV
- 400
26.59 USD
3 years ago
Mar 29, 2021
Sell 209 M USD
EQT Avatar Parent L.P.
10 percent owner
- 8674151
24.125 USD
3 years ago
Dec 15, 2020
Bought 115 K USD
WALSH MATTHEW M
Director
+ 5000
23 USD
3 years ago
Dec 15, 2020
Sell 306 M USD
EQT Avatar Parent L.P.
10 percent owner
- 14167717
21.62 USD
3 years ago
Dec 15, 2020
Bought 460 K USD
CASHMAN JAMES E III
Director
+ 20000
23 USD
3 years ago
Dec 15, 2020
Bought 506 K USD
McLean Stephen M.
Director
+ 22000
23 USD
3 years ago
Dec 15, 2020
Bought 5.64 K USD
Traynor Richard M.
SVP and General Counsel
+ 245
23 USD
7. News
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript seekingalpha.com - 1 week ago
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates Certara, Inc. (CERT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago. zacks.com - 1 week ago
Certara Reports Third Quarter 2024 Financial Results RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. globenewswire.com - 1 week ago
Certara to Participate in the Stephens Annual Investment Conference RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. globenewswire.com - 2 weeks ago
Certara Appoints John Reynders as New Independent Board Member RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. globenewswire.com - 1 month ago
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. globenewswire.com - 1 month ago
Certara Completes Acquisition of Chemaxon Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry. globenewswire.com - 1 month ago
Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon The final trades of the day with the Fast Money traders. youtube.com - 1 month ago
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. globenewswire.com - 1 month ago
Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: globenewswire.com - 2 months ago
Certara Launches Phoenix™ Version 8.5 Drug Development Software RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. globenewswire.com - 3 months ago
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
8. Profile Summary

Certara, Inc. CERT

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.6 B
Dividend Yield 0.00%
Description Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Contact 100 Overlook Center, Princeton, NJ, 08540 https://www.certara.com
IPO Date Dec. 11, 2020
Employees 1338
Officers Ms. Rona Anhalt Chief Human Resources Officer Dr. Robert P. Aspbury Ph.D. President of Certara Scientific Software Dr. Patrick F. Smith Pharm.D. President of Certara Drug Development Solutions Mr. Daniel Corcoran Chief Counsel Ms. Sheila Rocchio MBA Chief Marketing Officer Mr. Leif E. Pedersen President & Chief Commercial Officer Mr. John E. Gallagher III SVice President, Principal Accounting Officer & Chief Financial Officer Mr. Ron DiSantis Senior Vice President of Corporate Development Dr. William F. Feehery Ph.D. Chief Executive Officer & Director Mr. Max Kanevsky Chief Technology Officer